Acorda Therapeutics Inc.'s phase III fizzle in post-stroke walking difficulties (PSWD) of potassium channel blocker Ampyra (dalfampridine) didn't put much of a dent in the stock, but it made for the second development halt this year and put pressure on the rest of the pipeline, especially late-stage CVT-301, an inhaled levodopa for "off" episodes in Parkinson's disease.